Cortagen
Brain-cortex peptide bioregulator
Cortagen (Brain-cortex peptide bioregulator) is a longevity & bioregulators research compound. Neuro bioregulator targeting cerebral cortex tissue — proposed to support neuronal protein synthesis and recovery.
Cortagen quick facts
| Reported research dose | 2mg-5mg (per course) |
| Route | Subq |
| Frequency | 1x Daily · Daily (course) |
| Half-life | ~30 min |
| Forms | Injectable |
| Evidence level | Russian studies; limited |
Cortex-targeted neuro bioregulator — run in courses. Cortex-directed, and overlapping with Cerluten enough that most protocols run one. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, there is no lab for this — pick one repeatable cognitive measure and use it before and after. Run it as an experiment you measure, not a protocol you trust.
How Cortagen works
Neuro bioregulator targeting cerebral cortex tissue — proposed to support neuronal protein synthesis and recovery.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Cortagen
Buy Cortagen at Ion Peptide →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Cortagen
Graded by what exists behind each claim.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
📊 Correlative data
- Used in Russian practice for recovery after brain injury and in peripheral nerve conditions, and in the community for cognition. Reported experience is stronger for recovery contexts than for enhancement in healthy people, which is the pattern across most neuro-restorative compounds.
🧪 Theoretical / extrapolated
- Ala-Glu-Asp-Pro — a defined tetrapeptide derived from cortical tissue, proposed to support neuronal protein synthesis and regeneration.
- The shared claim across the Khavinson series: peptides this short are proposed to enter the cell nucleus and bind promoter regions of DNA, shifting tissue-specific gene expression.
- A restorative mechanism predicts a ceiling: if the action is normalizing expression toward a healthy baseline, there is more room to move in damaged tissue than in intact tissue.
How to read the Soviet clinical series → · The Khavinson series, in full →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Cortagen actually does
Cortagen is Ala-Glu-Asp-Pro. C17H26N4O9, 430.43 Da, isoelectric point 3.55, computed net charge about −2.06 at pH 7.4. That mapping is not vendor folklore: a 2002 immunology paper writes it out as ‘Cortagen (Ala-Glu-Asp-Pro)’ in its own abstract Khavinson 2002, which puts it among the minority of trade names in this catalog with a sequence stated in print.
Fact one: Cortagen and Epitalon are electrostatically the same molecule. Epitalon is Ala-Glu-Asp-Gly. Both compute to isoelectric point 3.55 and to about −2.06 net charge at blood pH; the masses are 430.43 and 390.36 Da. They differ at one position: proline against glycine. If the mechanism this whole family is sold on is electrostatic engagement with DNA and histone-modified chromatin, these 2 molecules present the same face to it — and one is sold for the brain cortex while the other is sold as the telomerase and pineal compound. The only thing left that could separate them is backbone conformation, and proline and glycine happen to be the 2 extremes of it: proline's ring locks the backbone angle, glycine has no side chain and is the most flexible residue there is. That is a real, testable difference. No published experiment has tested it.
Fact two: strip the alanine and this is a thymus peptide. Ala-Glu-Asp-Pro minus its N-terminal alanine is Glu-Asp-Pro, and the Thymalin literature names EDP explicitly — the reported activity of that thymus preparation is attributed to the short peptides Lys-Glu, Glu-Trp and Glu-Asp-Pro in its composition Kuznik 2021. So the tripeptide core of the brain product is an advertised active constituent of an immune product. Unlike the other single-alanine pairs in this catalog, this one can be checked, because Cortagen was actually put into immune tissue — see the next section.
Fact three, and it is an absence. The biophysical work that anchors the family's DNA claim — fluorescein-labeled peptides tracked into HeLa nuclei, then binding measured against defined oligonucleotides with discrimination of sequence and of cytosine methylation — covered Ala-Glu-Asp-Gly, Glu-Asp-Arg, Lys-Glu-Asp-Gly and Ala-Glu-Asp-Leu Fedoreyeva 2011. Ala-Glu-Asp-Pro is not in it. The member of this family with the largest gene-expression dataset has never been through the binding assay that is supposed to explain gene-expression datasets.
Cell, rodent, human — and where it stops
In immune cells, where it was the control that did nothing — and that is a point in its favor. Two 2002 studies ran Cortagen head-to-head with Vilon (Lys-Glu) and Epithalon (Ala-Glu-Asp-Gly). In mouse thymocytes, Vilon had the strongest comitogenic effect and the strongest action on membrane sphingomyelinase, Epithalon was moderate, and Cortagen produced no significant effect Khavinson 2002. In CBA mouse splenocytes all 3 raised interleukin-2 mRNA without an added inductor, with the response varying by peptide, concentration and duration, and Cortagen was the least pronounced of the 3 Kazakova 2002. Read fairly, that is evidence for tissue specificity: the cortex peptide is the weak one in immune tissue, which is what the catalog's claim predicts.
In explant culture it does hit its own tissue. Cortagen stimulated growth of explants from rat brain cortex, while Epithalon acted on subcortical structures, Livagen on liver and Vilon on thymus — and the same short report states the design logic outright: each synthetic peptide stimulated the tissue whose extract was used for its chemical synthesis Khavinson 2001. A 2002 paper then ran the 4 extracts (Cortexin, Epithalamin, Hepalin, Thymalin) alongside the 4 synthetics in one culture system across rats of different ages and reports the effects as concentration-dependent without giving the concentrations Khavinson 2002. The head-to-head ratio everybody would want is inside that experiment and is not in the record.
And now the finding this page exists for. The only transcriptome-scale experiment ever run on the brain-cortex peptide was run in the heart. Mouse myocardium, microarray, 15,247 transcripts screened: 234 clones changed significantly, corresponding to 110 known genes, with maximum up-regulation +5.42 and maximum down-regulation −2.86, and the paper compares Cortagen against Vilon, Epitalon and melatonin in the same tissue Anisimov 2004. Put that beside the immune results and the picture inverts: the peptide that did essentially nothing to thymocytes moved 110 genes in cardiac tissue. Both cannot be described as tissue specificity. And 22 years later there is still no cortical transcriptome for the cortical peptide — the tissue it is named for is the one tissue it has never been profiled in. No indexed paper reports a cortical transcriptome for it — PubTator3, 4 September 2026.
In a whole animal with a disease, and this is the one comparison the rest of the catalog cannot make. Rats with chronic brain ischemia, split by innate resistance to hypoxia into high- and low-resistant animals, were given either cortexin — the brain cortex extract — or cortagen, the synthetic peptide derived from it. Both accelerated recovery of disturbed individual behavior, and both prevented excessive activation of lipid peroxidation and the fall in antioxidant activity in brain tissue Zarubina 2011. Everywhere else in this family the human or animal evidence belongs to a mixture while the product sold is a single synthetic peptide from it; here, uniquely, somebody ran both arms in the same model. The abstract states no dose, no route, no duration and no group sizes, so what can be taken from it is the direction and the existence of the comparison, not its size — and that limitation is worth stating rather than papering over.
In humans: nothing for this peptide. The independent systematic review that pooled 24 randomized trials over 2,245 participants on cognitive endpoints, rating risk of bias moderate to high and certainty low to very low, is the outside view of the family and does not contain a Cortagen arm Alsulaimani 2021.
The obstacles. (1) Every positive whole-animal result is in an injured brain. Chronic ischemia is a disease model; a healthy adult is the arm nobody ran. (2) The doses are not in the record, so no course can be derived from the animal work. (3) Delivery: 4 residues is outside the di- and tripeptide range described for PEPT1, PEPT2, LAT1 and LAT2 Khavinson 2022, and subcutaneous injection removes the gut but not the blood-brain barrier. (4) The binding assay skipped it Fedoreyeva 2011.
Cortagen pharmacokinetics — how much of it actually gets in
This molecule has a chemical weakness none of its siblings has, and it sits at the last bond in the chain. In Ala-Glu-Asp-Pro the C-terminal linkage is Asp-Pro, and the aspartyl-prolyl bond is the most acid-labile peptide bond in protein chemistry. It is labile enough that protein chemists use it deliberately: dilute acid at roughly pH 2 and about 70 °C cleaves proteins selectively at Asp-Pro while leaving other bonds intact.
Now put a capsule in a stomach. Gastric contents sit at roughly pH 1.5–3.5, at 37 °C, for 1 to 2 hours. The pH is right; the temperature is about 33 °C below the standard cleavage condition. At an ordinary rate change of 2- to 3-fold per 10 °C that is roughly 10- to 35-fold slower than the laboratory protocol — slower, not absent, and over a 1–2 hour residence that predicts partial cleavage before any enzyme is involved. This is arithmetic from ordinary physical chemistry rather than a measurement: nobody has ever put this peptide in simulated gastric fluid and looked.
The same proline cuts the other way, which is the interesting part. A C-terminal proline blocks most carboxypeptidases, and bonds on either side of a proline resist ordinary exopeptidases — which is precisely why biology needed specialist enzymes for them, dipeptidyl peptidase-4 and prolyl oligopeptidase among them. So Ala-Glu-Asp-Pro is plausibly the most enzyme-resistant and the most acid-labile member of this family at the same time. That is the worst possible pairing for a swallowed product and a perfectly reasonable one for an injected one, and this catalog sells Cortagen injectable-only. The chemistry is the explanation, and no page anywhere gives it.
What is missing. There are 0 published pharmacokinetic measurements for this peptide in any species, so the card's ‘about 30 minutes’ is an expectation for an unmodified tetrapeptide written in the form of a measurement. No oral bioavailability figure exists either, so the honest move is to bound it: even at a generous 1 in 10 surviving the gut, an oral and an injected course differ about 10-fold in delivered material, and nothing published could distinguish 10-fold from 1,000-fold. And there are 0 biodistribution studies, so whether a 430 Da net-anionic peptide crosses into brain parenchyma after a subcutaneous dose is assumed rather than shown — on every page that sells it, including the ones written to sound technical.
What would have to be true, and how you would know it was not
Four predictions. The first is about the instrument rather than the compound, and it is the one that fools people.
1. A MoCA will not show anything, and that is not evidence the compound worked or failed. The Montreal Cognitive Assessment is scored out of 30 and a healthy adult under 60 typically sits at 26 to 30, so there is almost no room above the starting point — a ceiling effect. A move from 28 to 30 after a course is inside the test's own retest variability and its practice effect, especially if the same version is used twice. If you use it at all, use alternate forms and treat the result as uninformative in either direction.
2. The Trail Making Test part B, timed, is the honest instrument here, and it needs a baseline of your own before it means anything. It is continuous rather than capped, it is sensitive to processing speed and set-shifting, and it takes 3 minutes. Run it 3 times across a week before starting, which gives you your own spread, then at the end of a course and again 4 weeks later. Any change smaller than your own pre-course spread is nothing, and most reported cognitive improvements in this category are smaller than that.
3. pTau-217 should not move. This family's neurological literature reaches toward Alzheimer's pathology, and phosphorylated tau 217 is now the blood marker that tracks that pathology and correlates with amyloid burden. Nothing about a 10–20 day course of a tetrapeptide should shift accumulated tau phosphorylation, and predicting a null is predicting that this compound is not what the Alzheimer's-adjacent framing implies. Order it on physician direction if at all; it is a serious test with serious implications, not a self-experiment readout.
4. F2-isoprostane is the rodent finding's human counterpart and nobody has ever drawn it. The one whole-animal result for this peptide is suppression of lipid peroxidation in brain tissue of ischemic rats Zarubina 2011. The validated human measure of lipid peroxidation is urinary F2-isoprostane normalized to creatinine, retested at 3 to 6 months. The prediction cuts against the product: in a person without ischemia it should not change, because the rodent effect was measured in injured tissue and there is nothing published to say the effect exists without the injury.
What nobody has tested yet
Five experiments. The first one is 22 years overdue and the equipment has only got cheaper.
1. Nobody has run the array in the cortex. The 2004 study screened 15,247 transcripts in mouse heart and found 110 genes moving Anisimov 2004. The same animals, the same treatment and one extra dissection would have produced a cortical dataset. It did not happen then, and RNA sequencing in 6 mice would produce a better one now for a fraction of the 2004 cost. Until it exists, the gene-expression case for a brain peptide rests entirely on a heart, which is a sentence nobody in this market has written.
2. Nobody has run Ala-Glu-Asp-Pro against Glu-Asp-Pro. This is the alanine question in the one pair where both halves already have published claims: the tetrapeptide was inert in mouse thymocytes Khavinson 2002 while the tripeptide is named as an active constituent of a thymus preparation Kuznik 2021. Same thymocytes, same comitogenic assay, both molecules, one plate. If the tripeptide works where the tetrapeptide did not, 1 alanine is doing the organ assignment for this catalog and that is a genuinely important result. If they behave identically, the organ labels are marketing.
3. Nobody has put it in simulated gastric fluid. Peptide in 0.1 M hydrochloric acid with pepsin at 37 °C, sampled by LC-MS at 0, 30, 60 and 120 minutes, with the Asp-Pro cleavage products as the thing to look for. One day of work settles whether any oral cortex preparation containing this sequence delivers it, and the answer applies to every capsule in the category.
4. Nobody has compared the extract and the peptide in an uninjured animal. Cortexin and cortagen were run side by side in rats with chronic brain ischemia Zarubina 2011. The comparison that matters to a healthy person buying either one is the identical design without the ischemia, and it has never been published.
5. Nobody has put it through the family's own DNA assay. Ala-Glu-Asp-Gly, Glu-Asp-Arg, Lys-Glu-Asp-Gly and Ala-Glu-Asp-Leu were all labeled, tracked into nuclei and tested against defined oligonucleotides Fedoreyeva 2011. Adding Ala-Glu-Asp-Pro to that panel is the same protocol with a fifth vial, and it would say whether the peptide with the most transcriptional data in the family binds DNA at all.
Cortagen — its own safety story, not its class's
Four things this compound owns, and the first is hiding inside its best-known paper.
1. The heart microarray is a safety observation and has never been used as one. A peptide sold for the brain changed the expression of 110 genes in mouse myocardium, with individual changes up to +5.42-fold Anisimov 2004. No harm was identified, because no cardiac phenotype was measured — the study was a transcript screen. But the honest reading is uncomfortable and simple: the only tissue in which this compound's systemic reach has been profiled is not the tissue it is sold for, and the profile was not empty. Anyone with existing cardiac disease is making that decision without data, and without being told the data gap exists.
2. The people most likely to buy it are the people least able to tell whether it worked. The whole-animal evidence is in ischemic brain Zarubina 2011, and the reported human experience is strongest in recovery contexts rather than in enhancement. After a stroke or a head injury, spontaneous recovery is the dominant process for months, so a course started during that window will look effective no matter what it does. The protective move is not caution about the compound; it is a timed task with a personal baseline established before starting.
3. Switching between an oral cortex preparation and this injection is a chemistry change, not a convenience choice. The Asp-Pro bond makes the swallowed fraction unknown and probably reduced, while the injected fraction is not exposed to acid at all. Nobody can state the conversion because the gastric stability experiment has never been run, and a person moving between forms should assume the delivered amount changed by an unknown factor rather than assume it did not.
4. The situation where this page says stop rather than monitor. New one-sided weakness, sudden difficulty speaking, a first seizure, or a severe headache unlike any before are emergencies, and the harm this compound can do there is entirely a harm of delay — its own animal evidence comes from a chronic ischemia model, which is a diagnosis made with a scan and not with a peptide. There are 0 human studies of Cortagen and therefore 0 occasions on which a side effect could have been counted, so the empty adverse-event column describes the literature rather than the molecule.
Sources read for this page
- Anisimov SV, Khavinson VKh, Anisimov VN. Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray. Neuro Endocrinology Letters 2004;25(1-2):87-93 · PMID 15159690
- Zarubina IV, Shabanov PD. [Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia]. Eksperimental'naia i Klinicheskaia Farmakologiia 2011;74(2):8-15 [Russian] · PMID 21476278
- Khavinson VKh, Rybakina EG, Malinin VV, Pivanovich IY, Shanin SN, Korneva EA. Effects of short peptides on thymocyte blast transformation and signal transduction along the sphingomyelin pathway. Bulletin of Experimental Biology and Medicine 2002;133(5):497-499 · PMID 12420072
- Kazakova TB, Barabanova SV, Khavinson VKh, Glushikhina MS, Parkhomenko EP, Malinin VV, Korneva EA. In vitro effect of short peptides on expression of interleukin-2 gene in splenocytes. Bulletin of Experimental Biology and Medicine 2002;133(6):614-616 · PMID 12447482
- Khavinson VK. Tissue-specific effects of peptides. Bulletin of Experimental Biology and Medicine 2001;132(2):807-808 · PMID 11713572
- Khavinson VKh, Malinin VV, Chalisova NI, Grigor'ev EI. [Tissue-specific action of peptides in tissue culture of rats of various ages]. Advances in Gerontology 2002;9:95-100 [Russian] · PMID 12096446
- Kuznik B, Khavinson V, Shapovalov K, Linkova N, Lukyanov S, Smolyakov Yu, Tereshkov P, Shapovalov Yu, Konnov V, Tsybikov N. Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients. Advances in Gerontology 2021;11(4):368–376
- Fedoreyeva LI, et al. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow) 2011;76(11):1210–1219 · PMID 22117547
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group). The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis. Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
Cortagen — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Cortagen — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Cortagen moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Cortagen in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Cortagen
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Cortagen — frequently asked questions
What is Cortagen?
Cortagen (Brain-cortex peptide bioregulator) is a longevity & bioregulators research compound. Neuro bioregulator targeting cerebral cortex tissue — proposed to support neuronal protein synthesis and recovery.
Is the full Cortagen protocol on this page?
The reported research dose is on this page, along with how Cortagen works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Cortagen?
Cortagen has an approximate half-life of ~30 min, which is part of what determines how often it's dosed.
What's the evidence behind Cortagen?
Current evidence level: Russian studies; limited. Cortagen is offered for research purposes only and is not an approved medicine.
Cortagen inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Cortagen is used for
Cortagen appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Cortagen is the bdnf arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.